



POLICY STATEMENT

Updated Recommendations on the Use
of Meningococcal Vaccines

abstract

FREE

Since the last policy statement from the American Academy of Pediatrics (AAP) concerning meningococcal vaccine was published in 2011, 2 meningococcal conjugate vaccines have been licensed for use in infants (HibMenCY-TT and MenACWY-CRM). The Centers for Disease Control and Prevention (CDC) has published new recommendations, "Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices," which have been endorsed by the AAP. However, the CDC recommendations were published before licensure of MenACWY-CRM for infant use. This policy statement updates the AAP recommendations for use of meningococcal vaccines in children and adolescents. A more comprehensive review of background and technical information can be found in the CDC publication. *Pediatrics* 2014;134:400–403

Neisseria meningitidis is responsible for a spectrum of infections, such as meningitis, bacteremia, and pneumonia, and may be associated with long-term sequelae and death. Five serogroups of *N. meningitidis* (A, B, C, W, and Y) are responsible for the vast majority of disease in children and adults. Specific meningococcal serogroups appear to cause a preponderance of disease in certain age groups and geographic areas. For example, in the United States, *N. meningitidis* serogroup B is predominant in children younger than age 5 years, whereas serogroups C and Y are responsible for the majority of cases in adolescents. *N. meningitidis* serogroup A is hyperendemic in sub-Saharan Africa (the so-called "meningitis" belt) but it is rarely diagnosed in the United States.

For unknown reasons, the incidence of meningococcal disease has decreased in the United States since the late 1990s. The decrease started before the availability of the meningococcal conjugate vaccine and recommendations for routine meningococcal vaccine use in adolescents. Declines in incidence have occurred in all serogroups, including serogroup B, which is currently not included in any meningococcal vaccine licensed in the United States.

In the United States, 4 licensed meningococcal vaccines are available. One is a quadrivalent (A, C, W-135, Y) polysaccharide vaccine (MPSV4 [Menomune, Sanofi Pasteur, Inc, Swiftwater, PA]). There are 2 quadrivalent conjugate vaccines (A, C, W, Y) (MenACWY-D [Menactra, Sanofi Pasteur, Inc] and MenACWY-CRM [Menveo, Novartis Vaccines and Diagnostics, Inc, Cambridge, MA]), and 1 bivalent (C; Y) conjugate vaccine (HibMenCY-TT [MenHibrix, GlaxoSmithKline Biologicals, Research Triangle Park, NC]), which is also approved as a vaccine for *Haemophilus influenzae* type b (Table 1).

COMMITTEE ON INFECTIOUS DISEASES

KEY WORDS

meningococcus, meningococcal vaccine, adolescent vaccines, immunization schedule

ABBREVIATIONS

AAP—American Academy of Pediatrics
CDC—Centers for Disease Control and Prevention
Hib—*Haemophilus influenzae* type b

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

www.pediatrics.org/cgi/doi/10.1542/peds.2014-1383

doi:10.1542/peds.2014-1383

Accepted for publication May 15, 2014

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2014 by the American Academy of Pediatrics

TABLE 1 Licensed Meningococcal Vaccines: United States, 1981–2013

Formulation	Type	Trade Name	Manufacturer	Licensed (y)	Age Group	Dose(s)	Serogroups
MPSV4 ^a	Polysaccharide	Menomune	Sanofi Pasteur	1981	≥2 y	Single dose	A, C, W, and Y
MenACWY-D ^b	Conjugate	Menactra	Sanofi Pasteur	2005	11 to 55 y	Single dose	A, C, W, and Y
MenACWY-D ^b	Conjugate	Menactra	Sanofi Pasteur	2007	2 to 10 y	Single dose	A, C, W, and Y
MenACWY-D ^b	Conjugate	Menactra	Sanofi Pasteur	2011	9 to 23 mo	2-dose series	A, C, W, and Y
MenACWY-CRM ^c	Conjugate	Menveo	Novartis	2010	11 to 55 y	Single dose	A, C, W, and Y
MenACWY-CRM ^c	Conjugate	Menveo	Novartis	2011	2 to 10 y	Single dose	A, C, W, and Y
MenACWY-CRM ^c	Conjugate	Menveo	Novartis	2013	2 mo to 2 y	4-dose series	A, C, W, and Y
Hib-MenCY-TT ^d	Conjugate	MenHibrix	GlaxoSmithKline	2012	6 wk to 18 mo	4-dose series	C and Y

^a Package insert available at: <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Approvedproducts/UCM308370.pdf>

^b Package insert available at: <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Approvedproducts/UCM131170.pdf>

^c Package insert available at: <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Approvedproducts/UCM201349.pdf>

^d Package insert available at: <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Approvedproducts/UCM308577.pdf>

BACKGROUND AND RATIONALE

Meningococcal vaccines are recommended routinely for adolescents and for selected groups of children at increased or persistent risk for invasive meningococcal disease (Table 2). There are 2 types of meningococcal vaccines: (1) polysaccharide and (2) conjugated polysaccharide vaccines. Conjugated polysaccharide vaccines use a T-cell–dependent mechanism that results in a more robust primary immune response and immunologic memory and boosting potential, as compared with polysaccharide-only vaccines that use a T-cell independent mechanism. The new indications and newly licensed vaccines address immunization of younger children at increased risk for meningococcal disease.

This document provides a complete update of policy recommendations of the American Academy of Pediatrics for children and adolescents.

RECOMMENDATIONS

The following are meningococcal vaccination recommendations (Table 3):

1. For the pediatric population, an age-appropriate meningococcal conjugate vaccine is preferred to the meningococcal polysaccharide vaccine, unless there is a contraindication for the meningococcal conjugate vaccine.
2. Adolescents should be routinely immunized at 11 to 12 years of age and given a booster dose at

16 years of age with a quadrivalent conjugated meningococcal vaccine.

3. Adolescents who received their first dose at age 13 to 15 years should receive a booster at age 16 to 18 years at least 8 weeks or up to 5 years after their first dose.
4. Adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose.
5. Unvaccinated or previously vaccinated first-year college students through age 21 years living in residence halls who received their last dose before their 16th birthday (ie, incompletely vaccinated) should receive a single dose of quadrivalent meningococcal conjugate vaccine.
6. For individuals who are at increased risk for invasive meningococcal disease because of persistent complement (eg, C3, C5–C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia, a 2-dose primary series (MenACWY-D or MenACWY-CRM) is administered to individuals 2 to 55 years of age, and a 4-dose primary series (MenACWY-CRM or Hib-MenCY-TT) is administered to children 2 to 18 months of age. MenACWY-D can be administered as a 2-dose series to infants 9 to 23 months of age with persistent complement component deficiency, and in infants up to 23 months of age after the fourth dose of the primary pneu-

mococcal conjugate vaccine has been given in children who have functional or anatomic asplenia.

7. HIV infection is not an indication for routine MenACWY immunization before 11 years of age. However, HIV-infected children 11 years of age or older should be given a 2-dose primary series 8 to 12 weeks apart (MenACWY-D or MenACWY-CRM) with a single booster dose, consistent with recommendations for healthy adolescents.
8. For children older than age 2 years who have persistent risk for meningococcal disease because of complement component deficiency or asplenia, their primary series should include 2 doses of quadrivalent meningococcal conjugate vaccine 8 to 12 weeks apart (MenACWY-D or MenACWY-CRM).
9. For children 2 months to 6 years of age at persistent risk for meningococcal disease (Table 2), a booster dose should be given 3 years after the primary series and every 5 years thereafter. For children and adolescents 7 years or older at persistent risk for meningococcal disease (Table 2)

TABLE 2 Children at Increased Risk for Meningococcal Disease

Persistent complement component deficiencies (C3, C5–C9, properdin, factor D, and factor H)
Functional or anatomic asplenia
Travel to or reside in an area with hyperendemic or epidemic meningococcal disease
Residence in a community with a meningococcal outbreak

TABLE 3 Recommended Meningococcal Vaccines by Age Group

Age Group	Vaccine	Routine Recommendation	Dosing Schedule
2 mo to 10 y	MCV4-D (Menactra, Sanofi) ^a	High-risk only ^a High-risk only ^b High-risk only ^c	Primary <ul style="list-style-type: none"> • Age 9 to 23 mo: 2-dose series with 12 weeks between doses • Age 2 to 10 y: 1 dose Booster (for persons who remain at risk) <ul style="list-style-type: none"> • First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y • Every 5 y for children who received primary series after 7th birthday
	MCV4-CRM (Menveo, Novartis)		Primary <ul style="list-style-type: none"> • Age 2 to 6 mo: 4 doses at 2, 4, 6, and 12 mo • Age 7 to 23 mo: 2 doses should be given, with the 2nd dose given in the 2nd year of life • Age 2 to 10 y: 1 dose Booster (for persons who remain at risk) <ul style="list-style-type: none"> • First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y • Every 5 y for children who received primary series after 7th birthday
	HibMenCY-TT (MenHibrix, GSK)		Primary <ul style="list-style-type: none"> • Age 2 to 18 mo: 4-dose series with doses at 2, 4, 6, and 12 to 15 mo Booster (for persons who remain at risk) <ul style="list-style-type: none"> • Use MCV4-D or MCV4-CRM (see above)
11 to 21 y	MCV4-ACWY-D (Menactra, Sanofi)	Healthy and high-risk	Primary: healthy <ul style="list-style-type: none"> • Age 11 to 15 y: 1-dose primary series with booster at 16 to 21 y • Age 16 to 21 y: 1 dose, no booster necessary Booster: healthy <ul style="list-style-type: none"> • Age 16 to 21 y: 1 dose Primary: high risk <ul style="list-style-type: none"> • 2-dose primary series for those who have asplenia, HIV infection, or persistent complement component deficiency Booster (for persons who remain at risk) <ul style="list-style-type: none"> • First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y • Every 5 y for children who received primary series after 7th birthday
	MCV4-ACWY-CRM (Menveo, Novartis)	Healthy and high risk	Primary: healthy <ul style="list-style-type: none"> • Age 11 to 15 y: 1-dose primary series with booster at 16 to 21 y • Age 16 to 21 y: 1 dose, no booster necessary Booster: healthy <ul style="list-style-type: none"> • Age 16 to 21 y: 1 dose Primary: high risk <ul style="list-style-type: none"> • 2-dose primary series for those who have asplenia, HIV infection, or persistent complement component deficiency Booster (for persons who remain at risk) <ul style="list-style-type: none"> • First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y • Every 5 y for children who received primary series after 7th birthday
	HibMenCY-TT (MenHibrix, GlaxoSmithKline)	Not approved for this age group	

^a For children who have complement component deficiency or functional or anatomic asplenia or who are part of a community or organizational outbreak or who are traveling internationally to a region with hyperendemic or endemic meningococcal disease. For infants receiving the vaccine before travel, the 2 doses may be administered as early as 8 weeks apart. Infants who have functional or anatomic asplenia should wait until 2 years of age to prevent immune interference with PCV13.

^b For children who have complement component deficiency or functional or anatomic asplenia, or who are part of a community or organizational outbreak or who are traveling internationally to a region with hyperendemic or endemic meningococcal disease.

^c For children who have complement component deficiency or functional or anatomic asplenia, or who are part of a community or organizational outbreak. Hib-MenCY-TT is not recommended for use in children who are traveling internationally to a region with hyperendemic or endemic meningococcal disease. MCV4 should be used as booster doses for children who are given a primary series with Hib-MenCY-TT.

whose initial meningococcal vaccination was administered at 7 years or older, boosters of quadrivalent meningococcal conjugate should be repeated every 5 years (Table 4).

SPECIAL CIRCUMSTANCES

Routine vaccination against meningococcal disease is not recommended for healthy children 2 months to 10 years of age unless they are at increased or persistent

risk for meningococcal disease (Table 2). Hib-MenCY-TT (MenHibrix) may be administered to any infant for routine vaccination against *Haemophilus influenzae* type b (Hib). If Hib-MenCY-TT is used for

TABLE 4 Schedule for Booster Doses in Individuals Who Have Persistent Increased Risk for Invasive Meningococcal Disease

Age at Last MCV4 Dose	Duration Until Next Booster Dose
2 mo to 6 y	3 y ^a
>6 y	5 y

^a If last dose was HibMenCY-TT, the booster dose should be MenACWY-D or MenACWY-CRM.

protection against meningococcal disease, it should be used for all 4 doses of Hib vaccine, and other Hib-containing vaccines should not be used.

Limited data suggest that different conjugate vaccine products can be used interchangeably. If the same vaccine product used for the first dose is not available or if it is not known which vaccine product was used previously, administration of the vaccine should not be deferred if indicated, and any licensed age-appropriate conjugate vaccine can be administered.

The meningococcal vaccine is not routinely recommended for HIV-infected children until they reach 11 years of age, similar to other non-HIV-infected adolescents. HIV-infected children should receive 2 doses as their primary series.

A primary series consisting of 2 or more doses (depending on the age of the child) is indicated for children who have asplenia (reduced antibody response after a single primary dose) and complement component deficiency (higher antibody levels are needed for bacterial clearance mechanisms, such as opsonization, and more rapid antibody waning).¹

For travelers to areas with high meningococcal endemicity (parts of sub-Saharan Africa [the so-called “meningitis belt”] or the Hajj in Saudi Arabia), an age-appropriate meningococcal

vaccine that includes serogroups A and W is indicated. Periodically, there may be other areas in the world with meningococcal outbreaks (eg, serogroup W in Chile). Travelers need to monitor this possibility. Completion of the entire series is preferred before travel as follows: (1) for children <9 months of age: 2, 4, and 6 months of age (with booster at 12 to 18 months of age) with MenACWY-CRM; (2) for children ≥9 months to 23 months of age: 2 doses separated by at least 8 weeks (MenACWY-D) or 2 doses separated by at least 3 months (Menveo); and (3) for people >24 months of age: a single dose (MenACWY-D or MenACWY-CRM).

Pregnancy and breastfeeding do not preclude vaccination with MenACWY (Menactra or Menveo) or MPSV4 (Menomune) if indicated.

PRECAUTIONS AND CONTRAINDICATIONS

Vaccination with any meningococcal vaccine is contraindicated in people known to have a severe allergic reaction to any component of the vaccine. Conjugate vaccines that contain diphtheria or tetanus toxoid are contraindicated in people who have severe allergic reactions to these toxoids. A history of Guillain-Barré syndrome is not a contraindication or precaution for meningococcal vaccination. A previous temporal relationship between MenACWY-D and Guillain-Barré syndrome was not determined to be causally related. All currently licensed meningococcal vaccines are inactivated. They can be administered to people who are immunosuppressed as a result of disease or medication. However, the response to meningococcal vaccine in immunosuppressed children may be less than optimal.

COMMITTEE ON INFECTIOUS DISEASES, 2013–2014

Michael T. Brady, MD, FAAP, Chairperson – Red Book Associate Editor
 Carrie L. Byington, MD, FAAP
 H. Dele Davies, MD, FAAP
 Kathryn M. Edwards, MD, FAAP
 Mary Anne Jackson, MD, FAAP – Red Book Associate Editor
 Yvonne A. Maldonado, MD, FAAP
 Dennis L. Murray, MD, FAAP
 Walter A. Orenstein, MD, FAAP
 Mobeen H. Rathore, MD, FAAP
 Mark H. Sawyer, MD, FAAP
 Gordon E. Schutze, MD, FAAP
 Rodney E. Willoughby, MD, FAAP
 Theoklis E. Zaoutis, MD, FAAP

EX OFFICIO

Henry H. Bernstein, DO, FAAP – Red Book Online Associate Editor
 David W. Kimberlin, MD, FAAP – Red Book Editor
 Sarah S. Long, MD, FAAP – Red Book Associate Editor
 H. Cody Meissner, MD, FAAP – Visual Red Book Associate Editor

LIAISONS

Marc A. Fischer, MD, FAAP – Centers for Disease Control and Prevention
 Bruce G. Gellin, MD – National Vaccine Program Office
 Richard L. Gorman, MD, FAAP – National Institutes of Health
 Lucia H. Lee, MD, FAAP – US Food and Drug Administration
 R. Douglas Pratt, MD – US Food and Drug Administration
 Jennifer S. Read, MD, MS, MPH, DTM&H, FAAP – US Food and Drug Administration
 Joan L. Robinson, MD – Canadian Pediatric Society
 Marco Aurelio Palazzi Safadi, MD – Sociedad Latinoamericana de Infectología Pediátrica
 Jane F. Seward, MBBS, MPH, FAAP – Centers for Disease Control and Prevention
 Jeffrey R. Starke, MD, FAAP – American Thoracic Society
 Geoffrey R. Simon, MD, FAAP – Committee on Practice Ambulatory Medicine
 Tina Q. Tan, MD, FAAP – Pediatric Infectious Diseases Society

STAFF

Jennifer M. Frantz, MPH

REFERENCES

- Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2013;22:62(RR-2):1–28

Updated Recommendations on the Use of Meningococcal Vaccines
COMMITTEE ON INFECTIOUS DISEASES

Pediatrics 2014;134;400

DOI: 10.1542/peds.2014-1383 originally published online July 28, 2014;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/134/2/400>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Infectious Disease

http://www.aappublications.org/cgi/collection/infectious_diseases_sub

Vaccine/Immunization

http://www.aappublications.org/cgi/collection/vaccine_immunization_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:

<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Updated Recommendations on the Use of Meningococcal Vaccines COMMITTEE ON INFECTIOUS DISEASES

Pediatrics 2014;134;400

DOI: 10.1542/peds.2014-1383 originally published online July 28, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/134/2/400>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®

